Eva Segelov

Professional Summary: Professor Eva Segelov

Professor Eva Segelov is a distinguished medical oncologist and academic at Monash University, Australia. With a career spanning clinical practice, research, and education, she has made significant contributions to the field of oncology, particularly in gastrointestinal cancers and personalized medicine. Her work bridges clinical innovation with academic rigor, positioning her as a leading figure in cancer research and treatment.

Academic Background and Degrees

Professor Segelov holds the following qualifications, reflecting her extensive training in medicine and oncology:

• Bachelor of Medicine, Bachelor of Surgery (MBBS) – University of Sydney, Australia
• Fellow of the Royal Australasian College of Physicians (FRACP) – Specialization in Medical Oncology
• Doctor of Medicine (MD) – Research-focused degree in oncology

Research Specializations and Academic Interests

Professor Segelov’s research is centered on improving outcomes for patients with cancer through innovative clinical trials and translational research. Her key areas of interest include:

• Gastrointestinal cancers, with a focus on colorectal and neuroendocrine tumors
• Personalized medicine and targeted therapies in oncology
• Clinical trial design and implementation for cancer treatments
• Integration of patient-reported outcomes in cancer care

Career History and Appointments

Professor Segelov has held numerous prestigious positions across clinical and academic institutions, demonstrating her leadership in oncology:

• Professor of Oncology, Monash University, Melbourne, Australia (current)
• Director of Oncology, Monash Health, Melbourne, Australia (current)
• Previously, Associate Professor of Medicine, University of New South Wales (UNSW), Sydney, Australia
• Consultant Medical Oncologist, St Vincent’s Hospital, Sydney, Australia

Major Awards, Fellowships, and Honors

Professor Segelov has been recognized for her contributions to oncology and medical research through several notable accolades:

• Recipient of multiple National Health and Medical Research Council (NHMRC) grants for cancer research
• Recognized for leadership in clinical trials by the Australian Clinical Trials Alliance

Key Publications

Professor Segelov has authored and co-authored numerous impactful publications in high-ranking medical and oncology journals. A selection of her key works includes:

• Segelov, E., et al. (2021). 'Practical considerations for treating patients with cancer in the COVID-19 pandemic.' Journal of Oncology Practice.
• Segelov, E., et al. (2016). 'ICE CREAM Study: International trial on adjuvant chemotherapy in resected colorectal cancer.' Lancet Oncology.
• Segelov, E., et al. (2014). 'Therapeutic targeting of neuroendocrine tumors: Current options and future perspectives.' Expert Review of Anticancer Therapy.

Influence and Impact on Academic Field

Professor Segelov has had a profound impact on the field of oncology, particularly through her leadership in international clinical trials such as the ICE CREAM study, which has influenced adjuvant therapy protocols for colorectal cancer. Her advocacy for personalized medicine has contributed to the adoption of tailored treatment approaches, improving patient outcomes. Additionally, her mentorship of early-career researchers and clinicians at Monash University fosters the next generation of oncology experts.

Public Lectures, Committee Roles, and Editorial Contributions

Professor Segelov is actively involved in the broader academic and clinical community, contributing her expertise through various platforms:

• Regular invited speaker at international oncology conferences, including the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO)
• Chair and member of multiple clinical trial steering committees, including those under the Australasian Gastro-Intestinal Trials Group (AGITG)
• Editorial board member and reviewer for leading oncology journals